IRADIMED CORPORATION
IRMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring. The $1.15B market capitalization puts IRMD squarely in small-cap range for its industry. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Market Cap
$1.15B
Beta
0.91
P/E (TTM)
49.10
P/E (Fwd)
38.16
EPS (TTM)
$1.83
EPS (Fwd)
$2.35
ROE
25.0%
ROA
16.2%
Cash
$56.4M
Total Debt
$0
Free CF
$15.2M
52W Change
47.8%
Annual Financials
Cash vs Debt
IRADIMED CORPORATION reports $56.4M in cash and $0 in total debt. Free cash flow comes in at $15.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 25.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 16.2% further supports the picture of efficient asset utilization. Revenue has grown from $53.3M (2022) to $83.8M (2025), reflecting a 57% increase over the period.
As with any equity investment, IRMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing IRMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.